TPD has reached a pivotal moment.
But understanding what comes next requires more than fragmented intelligence.
The targeted protein degradation landscape is evolving rapidly. New degrader modalities, emerging targets, novel effector strategies and expanding therapeutic applications are continually reshaping the field. Yet critical insights remain dispersed across publications, patents, conference presentations and company disclosures, making it difficult to maintain a complete view of the science driving innovation.
The TPD H1 2026 Landscape Review brings these developments together into a single, data-driven analysis of the drug development landscape. Built using Beacon TPD intelligence, the series examines the modalities, targets, clinical activity and scientific milestones shaping the future of targeted protein degradation.
From the first FDA-approved PROTAC and the continued rise of GSPT1-targeting programs to growing momentum behind degrader-antibody conjugates (DACs) and the search for novel effector mechanisms beyond cereblon and VHL, the review highlights the developments advancing the field in 2026.
Part 1 of the series focuses on the TPD drug and trial landscape, exploring the assets, trials, modalities, and clinical developments shaping the evolution of targeted protein degradation.
The Drug Landscape
Explore the evolving TPD pipeline, including modality trends, target activity, emerging degrader technologies, and the programs shaping the next generation of protein degradation. Gain insight into the continued growth of PROTACs and molecular glues, the rise of DACs, and the targets attracting the greatest development activity.
The Trial Landscape
Analyze clinical activity across the TPD ecosystem, including trial initiations, disease trends, geographic expansion, and notable clinical milestones. Discover how degraders are advancing across oncology indications while gaining momentum in autoimmune and neurological disorders
The Commercial Landscape
Unpack the strategic and financial dynamics shaping the TPD field. Explore the partnerships, licensing activity, investment trends, and company strategies influencing the next phase of commercialization and industry growth.
Regulatory Announcement
Track the regulatory developments shaping the TPD landscape, from landmark approvals and clinical milestones to key designations and emerging validation signals. Understand the events influencing development strategies and industry confidence.
The Future of TPD
Assess the next chapter of targeted protein degradation. Explore the modalities, targets, and scientific advances expected to shape the field’s future, alongside the opportunities and challenges that will influence the next generation of degrader development.
Previous TPD Landscape Reviews
TPD 2025 Landscape Review
An analysis of the TPD landscape in 2025
TPD 2025 H1 Landscape Review
An analysis of the TPD landscape in H1 of 2025
TPD 2024 Landscape Review
An analysis of the TPD landscape in 2024
You May Also Be Interested In…
Learn More About TPD
- The Most Comprehensive Way to Search the TPD Drug Development Landscape: Unique search ontologies based on TPD drug and trial characteristics
- Market Leading Approach to TPD Preclinical & Clinical Data Curation: Manual curation of key TPD research and development data points by TPD research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search TPD company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
